-
1.再颁专利公开(公告)号：USRE41365E1
公开(公告)日：2010-06-01
申请号：US12378811
申请日：2009-02-18
CPC分类号： C12Q1/6844 , C12Q2525/301
摘要： Templates that are engineered to contain a predetermined sequence and a hairpin structure are provided by a nested oligonucleotide extension reaction. The engineered template allows Single Primer Amplification (SPA) to amplify a target sequence within the engineered template. In particularly useful embodiments, the target sequences from the engineered templates are cloned into expression vehicles to provide a library of polypeptides or proteins, such as, for example, an antibody library.
摘要翻译： 通过嵌套的寡核苷酸延伸反应提供被设计成含有预定序列和发夹结构的模板。 工程模板允许单引物扩增（SPA）扩增工程模板内的靶序列。 在特别有用的实施方案中，将来自工程化模板的靶序列克隆到表达载体中以提供多肽或蛋白质文库，例如抗体文库。
-
公开(公告)号：US20100104555A1
公开(公告)日：2010-04-29
申请号：US12290017
申请日：2008-10-24
IPC分类号： A61K38/17 , A61K38/16 , C07H21/04 , C12N15/63 , C12N1/21 , C12N5/10 , C12N5/06 , C07K16/00 , A61K31/7088 , A61K39/395 , C12Q1/70 , A61P31/12
CPC分类号： A61K39/29 , A61K31/7088 , A61K39/00 , A61K39/12 , A61K2039/505 , C07K14/005 , C07K16/109 , C07K2317/21 , C07K2317/55 , C07K2317/565 , C07K2317/92 , C12N2770/24222 , C12N2770/24234
摘要： The invention relates to modified hepatitis C virus E2 polypeptides that are effective in eliciting the production of cross-neutralizing antibodies against hepatitis C virus. The invention provides modified hepatitis C virus E2 polypeptides, preparations and pharmaceutical compositions containing them, as well as methods for using these modified E2 polypeptides.
摘要翻译： 本发明涉及有效引发产生针对丙型肝炎病毒的交叉中和抗体的改良型丙型肝炎病毒E2多肽。 本发明提供了修饰的丙型肝炎病毒E2多肽，含有它们的制剂和药物组合物，以及使用这些修饰的E2多肽的方法。
-
3.发明申请Methods for creating diversity in libraries and libraries, display vectors and methods, and displayed molecules 审中-公开在图书馆和图书馆中创建多样性的方法，显示向量和方法以及显示的分子公开(公告)号：US20100081575A1
公开(公告)日：2010-04-01
申请号：US12586273
申请日：2009-09-18
CPC分类号： C12N15/1027 , C07K16/005 , C07K16/087 , C07K16/1063 , C07K2317/565 , C12N15/1037 , C40B40/08 , C40B50/06
摘要： Provided herein are methods for generating diverse polypeptide and nucleic acid molecule libraries and collections, and the collections and libraries; methods for selecting variant polypeptides and nucleic acid molecules from the libraries; and molecules selected from the libraries. Exemplary of the polypeptides and nucleic acid molecules are antibodies and nucleic acids encoding the antibodies (including antibody fragments and domain exchanged antibodies). Also provided herein are methods of displaying polypeptides such as antibodies, for example on the surface of genetic packages, such as phage; and libraries and collections of the displayed polypeptides and vectors for producing the displayed polypeptides, libraries and collections. Exemplary of the displayed antibodies are domain exchanged antibodies.
摘要翻译： 本文提供了用于产生不同多肽和核酸分子文库和集合的方法，以及收集和文库; 从文库中选择变体多肽和核酸分子的方法; 和选自图书馆的分子。 多肽和核酸分子的示例是编码抗体的抗体和核酸（包括抗体片段和结构域交换的抗体）。 本文还提供了显示多肽例如抗体的方法，例如在遗传包装的表面上，例如噬菌体; 以及用于产生所显示的多肽，文库和集合的显示的多肽和载体的文库和集合。 显示的抗体的示例是域交换的抗体。
-
公开(公告)号：US07306906B2
公开(公告)日：2007-12-11
申请号：US10251085
申请日：2002-09-19
CPC分类号： C12N15/1093 , C12Q1/6844 , C12Q1/6853 , C12Q1/6855 , C12Q2537/157 , C12Q2533/101 , C12Q2525/301 , C12Q2525/186 , C12Q2525/161 , C12Q2525/155 , C12Q2525/131
摘要： Methods of amplifying nucleic acid have now been discovered which include the steps of: a) annealing a primer to a template nucleic acid sequence, the primer having a first portion which anneals to the template and a second portion of predetermined sequence; b) synthesizing a polynucleotide that anneals to and is complementary to the portion of the template between the location at which the first portion of the primer anneals to the template and the end of the template, the polynucleotide having a first end and a second end, wherein the first end incorporates the primer; c) separating the polynucleotide synthesized in step (b) from the template; d) annealing a nested oligonucleotide to the second end of the polynucleotide synthesized in step (b), the nested oligonucleotide having a first portion that anneals to the second end of the polynucleotide and a second portion having the same predetermined sequence as the second portion of the primer; e) extending the polynucleotide synthesized in step (b) to provide a terminal portion thereof that is complementary to the predetermined sequence; and f) amplifying the extended polynucleotide using a single primer having the predetermined sequence.
摘要翻译： 现已发现扩增核酸的方法，其包括以下步骤：a）将引物退火至模板核酸序列，所述引物具有与模板退火的第一部分和预定序列的第二部分; b）合成在所述模板的第一部分与所述模板退火的位置与所述模板的末端之间退火并与所述模板部分互补的多核苷酸，所述多核苷酸具有第一末端和第二末端， 其中所述第一端包含所述底漆; c）将步骤（b）中合成的多核苷酸与模板分离; d）将嵌套的寡核苷酸退火到步骤（b）中合成的多核苷酸的第二末端，所述嵌套的寡核苷酸具有与所述多核苷酸的第二末端退火的第一部分和具有与所述多核苷酸的第二部分相同的预定序列的第二部分 底漆; e）延伸在步骤（b）中合成的多核苷酸以提供与预定序列互补的其末端部分; 和f）使用具有预定序列的单一引物扩增延伸的多核苷酸。
-
5.发明申请POLYPEPTIDES AND ANTIBODIES DERIVED FROM CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND USES THEREOF 有权来自慢性淋巴细胞白血病细胞的多肽和抗体及其用途公开(公告)号：US20100239598A1
公开(公告)日：2010-09-23
申请号：US12715303
申请日：2010-03-01
IPC分类号： A61K39/395 , C07K16/00 , A61P35/00
CPC分类号： C07K16/42 , C07K16/3061 , C07K16/3076 , C07K2317/565 , C07K2317/622 , C07K2317/732 , G01N33/5005 , G01N33/5011 , G01N33/56972 , G01N33/57426 , G01N2333/70596 , G01N2500/20
摘要： Cancer treatments use a therapy that: 1) interferes with the interaction between CD200 and its receptor to block immune suppression thereby promoting eradication of the cancer cells; and 2) directly kills the cancer cells either by complement-mediated or antibody-dependent cellular cytotoxicity or by targeting cells using a fusion molecule that includes a CD200-targeting portion. The therapy includes the administration of novel antibodies, functional fragments thereof or fusion molecules containing portions thereof.
摘要翻译： 癌症治疗使用以下疗法：1）干扰CD200与其受体之间的相互作用以阻断免疫抑制，从而促进根除癌细胞; 和2）通过补体介导或抗体依赖性细胞毒性直接杀死癌细胞，或通过使用包含CD200靶向部分的融合分子靶向细胞。 治疗包括施用新型抗体，其功能片段或含有其部分的融合分子。
-
6.发明授权公开(公告)号：US07598353B2
公开(公告)日：2009-10-06
申请号：US12221134
申请日：2008-07-30
IPC分类号： C12P21/08
CPC分类号： C07K16/42 , C07K16/3061 , C07K16/3076 , C07K2317/565 , C07K2317/622 , C07K2317/732 , G01N33/5005 , G01N33/5011 , G01N33/56972 , G01N33/57426 , G01N2333/70596 , G01N2500/20
摘要： Cancer treatments use a therapy that: 1) interferes with the interaction between CD200 and its receptor to block immune suppression thereby promoting eradication of the cancer cells; and 2) directly kills the cancer cells either by complement-mediated or antibody-dependent cellular cytotoxicity or by targeting cells using a fusion molecule that includes a CD200-targeting portion. The therapy includes the administration of novel antibodies, functional fragments thereof or fusion molecules containing portions thereof.
-
7.发明授权公开(公告)号：US07598030B2
公开(公告)日：2009-10-06
申请号：US11631910
申请日：2005-07-08
IPC分类号： G01N1/70 , G01N33/53 , G01N33/567
CPC分类号： C07K16/3069 , A61K2039/505 , C07K16/00 , C07K16/2896
摘要： This disclosure relates to methods for selecting antibodies having desirable characteristics from a population of diverse antibodies. More specifically, this disclosure provides methods for identifying antibodies which bind to cancer cells, but which do not bind to human red or white blood cells or normal tissue cells. Antibodies of the disclosure can be used for therapeutic and/or diagnostic purposes.
摘要翻译： 本公开涉及从不同抗体群体中选择具有所需特征的抗体的方法。 更具体地，本公开提供了用于鉴定结合癌细胞但不结合人红细胞或白细胞或正常组织细胞的抗体的方法。 本公开的抗体可用于治疗和/或诊断目的。
-
8.发明申请公开(公告)号：US20090022745A1
公开(公告)日：2009-01-22
申请号：US12221134
申请日：2008-07-30
IPC分类号： A61K39/395 , C07K16/00 , A61P35/00
CPC分类号： C07K16/42 , C07K16/3061 , C07K16/3076 , C07K2317/565 , C07K2317/622 , C07K2317/732 , G01N33/5005 , G01N33/5011 , G01N33/56972 , G01N33/57426 , G01N2333/70596 , G01N2500/20
摘要： Cancer treatments use a therapy that: 1) interferes with the interaction between CD200 and its receptor to block immune suppression thereby promoting eradication of the cancer cells; and 2) directly kills the cancer cells either by complement-mediated or antibody-dependent cellular cytotoxicity or by targeting cells using a fusion molecule that includes a CD200-targeting portion. The therapy includes the administration of novel antibodies, functional fragments thereof or fusion molecules containing portions thereof.
-
9.发明授权公开(公告)号：US09150661B2
公开(公告)日：2015-10-06
申请号：US13344195
申请日：2012-01-05
IPC分类号： C07K16/42 , C07K16/30 , G01N33/50 , G01N33/569 , G01N33/574
CPC分类号： C07K16/42 , C07K16/3061 , C07K16/3076 , C07K2317/565 , C07K2317/622 , C07K2317/732 , G01N33/5005 , G01N33/5011 , G01N33/56972 , G01N33/57426 , G01N2333/70596 , G01N2500/20
摘要： Cancer treatments use a therapy that: 1) interferes with the interaction between CD200 and its receptor to block immune suppression thereby promoting eradication of the cancer cells; and 2) directly kills the cancer cells either by complement-mediated or antibody-dependent cellular cytotoxicity or by targeting cells using a fusion molecule that includes a CD200-targeting portion. The therapy includes the administration of novel antibodies, functional fragments thereof or fusion molecules containing portions thereof.
-
10.发明授权Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof 有权衍生自慢性淋巴细胞白血病细胞的多肽和抗体及其用途公开(公告)号：US08114403B2
公开(公告)日：2012-02-14
申请号：US12715303
申请日：2010-03-01
IPC分类号： A61K39/395
CPC分类号： C07K16/42 , C07K16/3061 , C07K16/3076 , C07K2317/565 , C07K2317/622 , C07K2317/732 , G01N33/5005 , G01N33/5011 , G01N33/56972 , G01N33/57426 , G01N2333/70596 , G01N2500/20
摘要： Cancer treatments use a therapy that: 1) interferes with the interaction between CD200 and its receptor to block immune suppression thereby promoting eradication of the cancer cells; and 2) directly kills the cancer cells either by complement-mediated or antibody-dependent cellular cytotoxicity or by targeting cells using a fusion molecule that includes a CD200-targeting portion. The therapy includes the administration of novel antibodies, functional fragments thereof or fusion molecules containing portions thereof.
摘要翻译： 癌症治疗使用以下疗法：1）干扰CD200与其受体之间的相互作用以阻断免疫抑制，从而促进根除癌细胞; 和2）通过补体介导或抗体依赖性细胞毒性直接杀死癌细胞，或通过使用包含CD200靶向部分的融合分子靶向细胞。 治疗包括施用新型抗体，其功能片段或含有其部分的融合分子。
-
-
-
-
-
-
-
-
-
搜索结果
19 条记录 (耗时 0.037 秒)